Discover our Antibody Libraries and what makes us different.
Andrew is a vocal proponent for the use of sequenced recombinant antibodies in research to improve reproducibility. He has frequently served as an expert witness in antibody patent cases involving some of the world’s best selling antibody drugs. Andrew has published over 130 peer-reviewed papers and is the inventor on numerous patents and patent applications.
Andrew holds a PhD from Cambridge University, where he studied under Nobel Laureate Cesar Milstein, the inventor of monoclonal antibodies, and also holds an MB BS (medical degree) from the University of London as well as a BA and MA from Oxford University.
Before joining Specifica, she was Research Assistant Professor in Experimental Therapeutics at the University of New Mexico and Associate Member of the UNM Comprehensive Cancer Center.
Her long-time collaboration with Andrew Bradbury, our co-founder and CSO, dates back to 2009 when she joined his laboratory as a post-doctoral fellow at the Los Alamos National Laboratory, first, and as Senior Scientist at the New Mexico Consortium.
Hans previously worked at Point B Capital on strategic financial advisory projects. He completed engagements for entities including Mars, MolsonCoors, the Seattle Cancer Care Alliance, Sutter Health, OncoCyte, the PolyClinic, BloodWorks Northwest, the Wisconsin Alumni Research Fund, and others. Prior to joining Point B Capital, he was a co-founder of Integra Ventures, a life science VC fund. He was also part of a founding management team for an agricultural biotechnology company that raised over $14 million of venture capital from an investor syndicate that included Venrock, Arch, Polaris and the Welcome Trust.
Hans has served on the boards of Clear Medical (acquired by Stericycle in 2011), Wellpartner (acquired by CVS Health in 2017) and C-SATS (acquired by Johnson & Johnson in 2018).
He has a Bachelor of Science in management from the U.S. Coast Guard Academy and earned his Master of Business Administration at the University of Colorado.
Before joining Specifica, Fortunato was an Assistant Research Professor in Experimental Therapeutics at the University of New Mexico in Albuquerque. Previously, he was a postdoctoral fellow in the laboratory of our co-founder Andrew Bradbury, at the Los Alamos National Laboratory. Fortunato has co-authored over 37 peer-reviewed scientific publications, and is the co-inventor on several patents and patent applications.
He holds a PhD in Molecular Medicine and a B.S. in Molecular Biology from the University of Trieste, Italy.
He brings over 8 years of experience in the development and characterization of therapeutic antibodies in academic and biotech environments. Within industry, he worked as an analytical chemist to characterize antibody-based products in a cGMP/GMP facility.
As a predoctoral trainee at the Spatiotemporal Modeling Center of New Mexico and Los Alamos National Labs, he incorporated both experimental and computational approaches to develop antibody-based products for treatment in leukemia.
Frank is a co-inventor of a patented antibody therapy that he recently adapted for use as a chimeric antigen receptor (CAR) T cell therapy in acute lymphoblastic leukemia. He holds a Ph.D. in Biomedical Science (University of New Mexico), an M.S. in Molecular & Cell Biology (San Diego State) and a B.S. in Molecular Biology (Cal Poly, San Luis Obispo).
Andre is a pharmacist and a PhD in Biochemistry, degrees conferred by the University of Sao Paulo (Brazil). He has experience in the design and engineering of phage display libraries, and also on software development for the analysis of large datasets generated by next-generation sequencing.
His main research focus was always protein-protein interactions, having worked and authored papers related to the subject in the fields of computational chemistry, neglected diseases and cancer. He was awarded three fellowships from the Sao Paulo Research Foundation during his scientific training.
Andre was a founder and served as president of the non-profit pharmaceutical consulting company of the Pharmacy School of the University of Sao Paulo.
During his undergraduate and graduate studies, Tom utilized Saccharomyces cerevisiae to identify and characterize essential molecular components that regulate DNA replication, DNA repair, chromosome segregation, and ribosomal DNA maintenance.
After obtaining his PhD, Tom conducted postdoctoral research at Princeton University, holding a number of fellowships (Burroughs Wellcome Fund research fellow, a New Jersey Commission on Cancer Research fellow, a Ford Foundation fellow, and a Keystone Symposia fellow) for his work using S. cerevisiae and Schizosaccharomyces pombe to identify and characterize important molecular pathways that mediate genome stability and telomere maintenance in the presence of endogenous and exogenous stress.
Tom entered the antibody space in 2019, joining NovaRock Biotherapeutics in New Jersey as a senior scientist and lead for molecular design. He leveraged his expertise to engineer recombinant expression vectors and proteins to produce monoclonal, bi-specific, and multi-specific antibodies. Tom was also a project lead for one of the company’s therapeutic antibody candidates, centrally involved with the identification of monoclonal antibodies derived from hybridoma screens and spearheaded development/implementation of pipeline improvements streamlining molecular cloning workflows.
Camila is a chemist and a PhD in Biochemistry, degrees conferred by the University of Sao Paulo (Brazil). She has extensive research experience in cell-based assays, flow cytometry, fluorescent activated cell sorting and CRISPR/Cas9 genome engineering.
Camila managed a GMP facility for human pancreas processing into islets for diabetes treatment, implemented pre-clinical trial protocols and designed a biomaterial for cell encapsulation, aiming to avoid immunosuppression and to attenuate host post transplantation immune response. During her scientific training, she was awarded two fellowships from the Sao Paulo Research Foundation and three honorable mentions at scientific conferences.
Camila also worked in the pharmaceutical industry developing and conducting biological assays to evaluate the potency and stability of new biological drugs, according to international pharmacopoeial specifications.
David holds a BSc. in Applied Molecular Biology, specialising in Medical Microbiology and Medical Biotechnology from the University of East London, a University College London MSc in Applied Molecular Biology & Biotechnology and a PhD in X-ray crystallography obtained in the Rosalind Franklin Laboratory, Birkbeck College University of London. David also obtained a Post Graduate Certificate in Education from the University of Sussex.
Prior to working at Specifica, David humanised several FDA approved antibody therapies including Cimzia ®that is used for the treatment of reducing Crohn’s disease, severe active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderate-to-severe plaque psoriasis. He enjoys challenging scientific roles that benefit other people’s lives.
Laura has a long-held interest in human therapeutics. As a PhD candidate at Stanford, her research focused on using adeno-associated virus vectors for gene therapy. She developed a novel next-generation sequencing strategy for interrogating genomic and epigenetic parameters governing nuclease-free, targeted integration of sequences in human cells using adeno-associated virus vectors. She has experience with targeted genomic sequencing strategies, design of next-generation sequencing libraries, and integrating targeted sequencing data with human genomic and epigenetic data to identify associations between the two.
As a predoctoral intern in the Theoretical Biology and Biophysics group at Los Alamos National Laboratory, Laura developed machine learning models for predicting changes in protein conformation.
Laura previously competed for the United States biathlon team on the World Cup and at the 2010 Winter Olympic Games in Vancouver, Canada.
During her PhD, she developed experience in protein production in E.coli and protein characterization. She also evaluated a novel sensor for the detection and photo-oxidation of amyloid plaques involved in Alzheimer’s disease. During her scientific training she was awarded 2 honorable mentions at scientific conferences and 1 honorable mention from the University of New Mexico as “Outstanding Graduate Student”.
Adeline has also worked in the pharmaceutical industry (UCB Pharma, Belgium and Allergan, UK) where she developed and optimized the production of monoclonal antibodies in 2L and 10L bioreactors, and also evaluated alternative technologies such as disposable bioreactors. Later she joined a biotechnology company, Trait Biosciences, USA, where she participated in the design and scale up of a fermentation process for the production of water-soluble cannabinoid in yeast cells in 2L and 600L bioreactors.
Luis is a Scientist with the New Mexico Consortium and collaborates with Specifica to develop new methods to select and characterize antibodies discovered using in vitro display.
Luis holds a PhD in Biochemistry from the University of Sao Paulo, Brazil. During his PhD, he developed experience in small-peptide phage display, molecular biology and immunobiology, using phage display to study the epitopes of neglected tropical diseases and find inhibitors of human transcription factors involved in malignancies. He was awarded financing from the Brazilian Council for Scientific and Technological Development for this research.
During his undergraduate studies in Peru, he gained experience in diverse fields of biological sciences. He isolated a lectin from an Andean plant and studied its possible medical applications, for which his bachelor thesis was given an honorable mention. Luis has experience working in multidisciplinary teams and is interested in applying his acquired knowledge to contribute to Specifica’s antibody discovery campaigns.
She studied molecular ecology with an emphasis in landscape and population genetics of cottonwoods across the southwestern United States. For 15 years her work in sequencing core facilities supported molecular genetics and genomics research in a wide variety of programs.
Before joining Specifica, she worked as a Research Associate with Pebble Labs in bacterial cloning and transgenic.
Has previous experience with project and lab management. Appreciates collaborating with scientists to generate meaningful tools and technologies that seek to make difference.
Christy is an experienced Researcher with a demonstrated history of working in academia and clinical laboratories. Skilled in the areas of molecular biology, cell biology, immunological techniques, and lab management.
Prior to joining Specifica, Christy was a Researcher and Lab Manager at the University of New Mexico, and performed Molecular testing at TriCore Reference Laboratories.
Christy is a lifelong New Mexican, and appreciates working with the talented and knowledgeable group of Scientists at Specifica.
Since graduating, Esteban has transitioned from field/greenhouse-oriented research to molecular biology. Prior to starting at Specifica he worked for 2 years in the biotech industry, gaining experience in broad molecular techniques. He has a deep love of biological sciences and his home state of New Mexico.
Alfonso holds a B.S. in General Biology and an M.S. in Natural Sciences: Ecology from New Mexico Highlands University. During his undergraduate studies, Alfonso worked in a genetics lab where his research project focused on male reproductive biology. As a graduate student, he studied how invasive bullfrogs impact a native toad species.
Alfonso worked at LabCorp: Integrated Genetics, where he was involved with testing samples to identify chromosomal abnormalities, obtaining an ASCP certificate in Cytogenetics while there. He worked at Viome as a technician evaluating gut microbial richness, inflammatory activity, and metabolic fitness, and gaining experience with liquid handlers, preparing libraries, and NGS before being promoted to their Quality Control lead of equipment performance and verifying sample documentations. During the pandemic, Alfonso was the evening lab supervisor at Atlas Genomics where he was responsible for managing a team of technicians, processing COVID-19 samples for movie productions. Prior to joining Specifica, Alfonso was the only scientist at Prosel Biosciences, where he was responsible for developing algal strains to produce industrial enzymes and plant based food proteins.
Alfonso has 12 years experience in biological research and laboratory production. Specifica has offered him new experiences that will help him grow as a scientist.
Hallie has a B.S. and M.S. in Biological Sciences from Mississippi State University. Her graduate work focused on plant defense pathways in agricultural crops. At MSU she established a growing love for biology and research. Prior to starting at Specifica Hallie worked in the biotech industry, obtaining experience in various molecular techniques. She enjoys working at Specifica and looks forward to learning from the scientists and coworkers.
Before working at Specifica, Jaime was a lab and facilities technician for the New Mexico Consortium and then for Pebble Labs. These jobs gave him the experience and knowledge that help him maintain the facilities at Specifica. Prior to these jobs, Jaime worked as a field biologist in El Paso, Texas, surveying military land for endangered and invasive plant species.
Jaime has a BS in biology from New Mexico State University in Las Cruces, New Mexico. During his undergraduate work, he worked in a lab on campus focusing on animal communication in avian species. His work on contact calls in Thick-billed Parrots (Rhynchopsitta pachyrhynca) in particular, helped support future translocation experiments on the endangered parrot species.
Jaime is excited to be a part of the team at Specifica and appreciates the opportunity.
Find out more about
what we do
A Look Inside Specifica’s Purpose Built Laboratories